Your AI-Trained Oncology Knowledge Connection!
Arvind Dasari, MD, examines the progression-free survival and overall survival data from the FRESCO-2 trial, comparing the results to the original FRESCO trial, and discussing the implications for the treatment of heavily pretreated metastatic colorectal cancer patients.
Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients who had exhausted all standard treatment options, including cytotoxic chemotherapy, targeted therapies, anti-VEGF agents, and BRAF inhibitors for those with BRAF mutations.
Arvind Dasari, MD, explores the adverse event profile of Fruquintinib, highlighting its apparent tolerability, while emphasizing the importance of gathering real-world data to further assess the adverse event profile of this medication in clinical practice.
